Richy Agajanian - 10 Jun 2022 Form 4 Insider Report for Oncology Institute, Inc. (TOI)

Reporting relationship: 10%+ Owner
Issuer ticker: TOI
Reported as of: 10 Jun 2022
Net transaction value: -$1,545,000
SEC form: 4
Accepted by SEC: 14 Jun 2022, 19:12:42 UTC
Prior SEC filing: 13 May 2022
Source filing: View source filing
Reporting owner signature: /s/ Richy Agajanian, M.D., for himself and as the President and Chief Executive Officer of Jimmy Holdings, Inc.

Key filing fact

Richy Agajanian filed Form 4 for Oncology Institute, Inc. (TOI) on 14 Jun 2022.

Key facts

This page summarizes Richy Agajanian's Form 4 filing for Oncology Institute, Inc. (TOI).
1 reported transaction and 1 derivative row are listed below.
Accepted by SEC: 14 Jun 2022, 19:12.

Change

Previous filing in this sequence was filed on 13 May 2022.
Current net transaction value: -$1,545,000.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

TOI transaction Derivative

Stock Option (right to buy)

Sale

Transaction value: $1,545,000
Shares: -300,000
Change %: -50%
Price: $5.15^*
Shares after: 296,075
Date: 10 Jun 2022
Ownership: See Footnote
Underlying class: Class A Common Stock
Underlying amount: 300,000
Exercise price: $0.8500
Footnotes: F1, F2

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Section 16 status

Richy Agajanian is no longer subject to Section 16 filing requirements. Form 4 or Form 5 obligations may still apply in specific circumstances.

Explanation of responses 2 footnotes

Footnote F1

These stock options were received by Dr. Agajanian's spouse on November 12, 2021 in connection with a business combination. As of that date, 459,475 of the options were vested and 136,600 remained subject to vesting at the rate of 12,418 options each month, subject to Dr. Agajanian's spouse's continued employment with the issuer.

Footnote F2

Held by Dr. Agajanian's spouse. The reporting persons disclaim beneficial ownership of these securities.